Reto Wittwer
Directeur Financier/CFO chez Cardiorentis AG
Profil
Reto Wittwer is currently the Chief Financial Officer & Director at DiNAQOR AG and the Chief Financial Officer & Executive Vice President at Cardiorentis AG.
He is a graduate of the University of St. Gallen and the University of Zurich.
Postes actifs de Reto Wittwer
| Sociétés | Poste | Début |
|---|---|---|
Cardiorentis AG
 Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Directeur Financier/CFO | 10/01/2016 |
DiNAQOR AG
 DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Directeur Financier/CFO | - |
Formation de Reto Wittwer
| University of Zurich | Graduate Degree |
| University of St. Gallen | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cardiorentis AG
Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Health Technology |
DiNAQOR AG
DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Health Technology |
